Alternating hemiplegia of childhood (AHC) is a rare neurological disorder characterized by episodes of temporary paralysis affecting one side of the body, often accompanied by involuntary eye movements and developmental delays. According to research published in PubMed Central, AHC typically manifests in infants and young children, presenting diagnostic and therapeutic challenges for clinicians across paediatric neurology.
A Genetic Foundation Emerges
Recent advances in genetic sequencing have revolutionized understanding of AHC. Mutations in the ATP1A3 gene, which encodes a sodium-potassium pump protein essential for neuronal function, account for the majority of AHC cases. Research from Nature Medicine has demonstrated that these mutations disrupt the normal function of brain cells, leading to the episodic paralysis characteristic of the disorder.
The ATP1A3 gene functions as a critical regulator of ion balance across cell membranes. When mutated, this imbalance triggers the abnormal neural activity that produces AHC symptoms. Clinicians now recognize that genetic testing has become essential for confirming diagnosis and enabling families to understand the inherited nature of the condition.
Clinical Presentation and Diagnostic Challenges
AHC manifests through episodic hemiplegia—temporary one-sided weakness or paralysis—that can alternate between sides of the body. Episodes typically last hours to days and may be triggered by stress, illness, or fatigue. According to data from The New England Journal of Medicine, affected children often experience nystagmus (involuntary eye movements) and developmental regression, which can significantly impact cognitive and motor milestones.
Diagnosis remains challenging because episodes are often intermittent and imaging studies such as magnetic resonance imaging (MRI) typically appear normal between attacks. This has historically led to misdiagnosis or delayed recognition, with some children incorrectly diagnosed with epilepsy or conversion disorder. Early genetic testing is now recognised as the gold standard for confirmation and can spare families from prolonged diagnostic odysseys.
Paediatric neurologists at National Institutes of Health-affiliated centres emphasise that a detailed history of symptom timing, laterality, and associated features—combined with ATP1A3 genetic sequencing—provides the most reliable diagnostic pathway.
Treatment Strategies and Clinical Management
Currently, no cure exists for AHC, but several pharmacological agents have demonstrated efficacy in reducing episode frequency and severity. Flunarizine, a calcium channel blocker, has become a first-line therapy in many centres, with clinical trials showing meaningful reduction in attack burden. Supportive care—including physiotherapy, educational support, and family counselling—remains cornerstone management.
Research published in The Lancet indicates that early intervention with appropriate medications, combined with aggressive management of triggers, can substantially improve quality of life for affected children and reduce long-term neurological complications. Recent interest in targeted therapies directed at ATP1A3 dysfunction represents a promising frontier for future treatment development.
Mutations in the ATP1A3 gene account for approximately 70–80% of confirmed alternating hemiplegia of childhood cases, and genetic testing now enables accurate diagnosis and family counselling.
— Researchers at National Institutes of Health (Nature Medicine, 2024)
Key Clinical Features of Alternating Hemiplegia of Childhood
Source: National Institutes of Health, Nature Medicine (2024) | Georgian Medical Journal News
Key takeaways
- AHC is a rare genetic neurological disorder caused primarily by ATP1A3 mutations, affecting sodium-potassium pump function in the brain
- Episodes of temporary one-sided paralysis typically begin before age 18 months and may alternate sides or recur unpredictably
- Genetic testing provides definitive diagnosis where MRI and traditional neuroimaging are normal; early diagnosis enables appropriate management and family planning
- Flunarizine and other pharmacological agents reduce attack frequency, though no cure currently exists; multidisciplinary care is essential
Frequently asked questions
What causes alternating hemiplegia of childhood?
AHC is caused by mutations in the ATP1A3 gene, which encodes a protein essential for maintaining ion balance in nerve cells. When this protein malfunctions, abnormal electrical activity in the brain triggers episodes of temporary paralysis. According to research in PubMed Central, approximately 70–80% of AHC cases carry ATP1A3 mutations.
Can AHC be cured?
Currently, no cure exists for AHC. However, medications such as flunarizine can reduce the frequency and severity of episodes, and multidisciplinary management—including physiotherapy, cognitive support, and trigger avoidance—significantly improves quality of life. Emerging research into ATP1A3-targeted therapies offers potential for future breakthroughs.
How is AHC diagnosed?
Diagnosis combines clinical history (detailed description of episodes, timing, and triggers) with ATP1A3 genetic testing, which is now considered the gold standard. Brain imaging such as MRI is typically normal between episodes, making genetic testing essential for confirmation and ruling out other conditions.
Ongoing research into ATP1A3 dysfunction and neuroprotective strategies offers hope for improved treatments in the coming years. Rare disease registries and international collaboration are accelerating the pace of discovery, and families affected by AHC now have access to more informed diagnosis and evidence-based management than ever before.
Source: Understanding alternating hemiplegia of childhood, a rare disorder
Related reading: Explore more on medical research breakthroughs and advances in neurological treatment on Georgian Medical Journal News.